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Heterogeneity of primary outcome measures
used in clinical trials of treatments for
intermediate, posterior, and panuveitis
Alastair K. Denniston1,2* , Gary N. Holland3, Andrej Kidess1, Robert B. Nussenblatt4, Annabelle A. Okada5,
James T. Rosenbaum6 and Andrew D. Dick7,8,9
Abstract
Background: Uveitis describes a heterogeneous group of conditions characterized by intraocular inflammation.
Since most of the sight-threatening forms of uveitis are individually rare, there has been an increasing tendency for
clinical trials to group distinct uveitis syndromes together despite clear variations in phenotype which may reflect
real aetiological and pathogenetic differences. Furthermore this grouping of distinct syndromes, and the range of
manifestations within each uveitis syndrome, leads to a wide range of possible outcome measures. In this study we
wished to review the degree of consensus or otherwise in the choice of primary outcome measures for registered
clinical trials related to uveitis.
Methods: Systematic review of data provided in clinical trial registries describing clinical trials dealing with medical
treatment of intermediate, posterior, or panuveitis through 01 October 2013. We reviewed 15 on-line clinical trial
registries approved by the International Committee of Medical Journal Editors. We identified all that met the
following inclusion criteria: prospective, interventional design; target populations with intermediate, posterior or
panuveitis; and one or more pre-specified outcome measures that were related to uveitis. Primary outcome
measures were classified in terms of type (efficacy or safety or both; single, composite, or multiple); dimension
(disease activity, disease damage, measured or patient-reported visual function); and domain (the specific study
variable being measured).
Results: Of 195 registered uveitis studies, we identified 104 clinical trials that met inclusion criteria. There were 14
different domains used as primary outcome measures. Among clinical trials that utilized primary outcome measures
of treatment efficacy (n = 94), 70 (74 %) used a measure of disease activity (vitreous haze in 40/70 [57 %]; macular
oedema in 19/70 [27 %]) and 49 (70 %) used a measure of visual function (visual acuity in all cases). Multiple
primary outcome measures were used in 23 (22 %) of 104 clinical trials. With regard to quality, in 12 (12 %) of 104
clinical trials, outcome measures were poorly defined. No clinical trial utilized a patient-reported study variable as
primary outcome measure.
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Conclusions: This systematic review highlights the heterogeneity of outcome measures used in recent clinical trials
for intermediate, posterior, and panuveitis. Current designs prioritize clinician-observed measures of disease activity
and measurement of visual function as outcome measures. This apparent lack of consensus regarding outcome
measures for the study of uveitis is a concern, as it prevents comparison of studies and meta-analyses, and weakens
the evidence available to stake-holders, from patients to clinicians to regulators, regarding the efficacy and value of
a given treatment.
Keywords: Uveitis, Clinical trials, Outcome measures, Endpoints, Composite endpoints
Introduction
Uveitis describes a heterogeneous group of conditions
characterized by intraocular inflammation. Most uveitis
syndromes are individually rare, but for taxonomic and
clinical convenience are commonly grouped according
within an anatomical classification as being anterior,
intermediate, posterior, or pan-uveitis [1–7]. The most
sight-threatening forms are those that affect the more
posterior structures of the eye – intermediate, posterior
and pan-uveitis These three anatomical categories of
uveitis often share the need for similar therapeutic strat-
egies (usually systemic drug treatment) and are com-
monly grouped together in clinical trials, despite the
wide range of systemic disease associations and clinical
syndromes they represent. Intermediate, posterior and
panuveitis each have an estimated prevalence of around
5-10/100 000 in Europe and 13-25/100 000 in the USA
[1–6]. Evidently the individual syndromes are much
rarer with over 30 definable uveitis syndromes, many of
which may be classed as ‘very rare’ with a prevalence of
less than or equal to 1 per 100 000 [3–6]. Examples in-
clude Sympathetic Ophthalmia, Birdshot Chorioretino-
pathy, Acute Posterior Multifocal Placoid Pigment
Epitheliopathy and Serpiginous Choroidopathy. It should
be noted that although individual uveitis syndromes are
rare, they are collectively an important cause of vision
loss, believed to account for 15 % of total blindness in
the western world [1–3].
Research into the treatment of uveitis faces a number of
challenges, with few randomized controlled clinical trials
(RCTs) undertaken, and even fewer that demonstrate
treatment benefit [8]. There are wide-ranging practices
amongst specialists in their approaches to the treatment
of uveitis, with most specialists citing a lack of evidence to
support treatment decisions [9]. The advent of new intra-
vitreal therapies is providing even greater choice and un-
certainty for patients and clinicians [10–12].
We have argued that a fundamental obstacle to success-
ful clinical trials dealing with uveitis is the lack of high-
quality outcome measures [8]. Currently, vitreous haze
score, as defined by Nussenblatt and associates [13], is a
disease activity surrogate endpoint that is accepted by the
United States Food and Drug Administration (FDA) for
clinical trials that it reviews. This score utilizes a subjective
six-point (0, 0.5, 1, 2, 3, or 4+) ordinal scale of the cloudi-
ness of the vitreous humor. It has the advantages of being
non-invasive and widely available, but it has significant
inter-observer variability [14, 15]. Consequently a two-
step change has been required to be considered significant
[14], which is challenging, as most uveitis falls within the
lower grades (2+ or less). Success in these clinical trials re-
quires a combination of a near-perfect drug (including
large effect; effect in almost all recipients, despite subject
heterogeneity; and an acceptable side-effect profile) and a
near-perfect study (successful recruitment; minimal drop-
out; and minimal errors or missing data) [8].
Furthermore, a lack of consensus over which outcome
measure(s) to use, and how to measure them, results in
disparity of study design which limits evidence synthesis
and prevents the pooling of study data for meta-analysis.
An ability to compare new results to other studies is
often a key requirement of regulatory authorities and
health funders when evaluating and licensing novel ther-
apeutics, and in this regard the evidence-base for uveitis
consistently falls short. But issues around consistency of
outcomes and their reporting are not confined to uveitis;
indeed, there is growing recognition of the cost of ‘re-
search waste,’ in which issues, such as non-reporting or
selective reporting of data, inappropriate end-point se-
lection, and inadequate trial design, among other factors,
all contribute to a scenario in which ‘billions of dollars
in investment are wasted’ [16].
In light of these problems, we have investigated the
spectrum of outcome measures used in uveitis clinical
trials, particularly focusing on those trials dealing with
intermediate, posterior, and panuveitis. This systematic
review surveys all such therapeutic clinical trials regis-
tered in databases approved by the International Com-
mittee of Medical Journal Editors (ICMJE) through 01
October 2013. We present the primary outcome
measures identified in all these studies, noting the rela-
tive use of single, composite, and multiple outcomes,
and the heterogeneity of outcome selection. In addition,
we assess these data in terms of their potential impact
on the clinical trials environment within the subspecialty
of uveitis. We believe that the challenges of outcome
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selection in uveitis trials may be relevant to other sectors
of the rare disease community faced with designing clin-
ical trials for patients with syndromes that are individually
rare and which exhibit a wide range of clinically-relevant
manifestations.
Methods
Identification of clinical trial registries
All clinical trial databases that were registered with, and ap-
proved by, the ICMJE as of 01 October 2013 were identified
[http://www.icmje.org/recommendations/browse/publishin
g-and-editorial-issues/clinical-trial-registration.html ] Inclu
ded were those listed on the World Health Organization
(WHO) International Clinical Trials Registry Platform
(ICTRP) [http://www.who.int/ictrp/network/primary/en/]
and the United States National Institutes of Health (NIH)
“clinicaltrials.gov” website, [https://clinicaltrials.gov ] which
is a data provider to the WHO ICTRP. The ICMJE states
that it endorses those registries that meet the following
requirements: accessible to the public at no charge;
open to all prospective registrants; managed by a not-
for-profit organization; have a mechanism to ensure the
validity of the registration data; are electronically
searchable; and include a minimum 20-item trial
registration dataset at the time of registration and be-
fore enrollment of the first participant (available at
www.who.int/ictrp/network/trds/en/index.html ). In its
September 2004 editorial, the ICMJE announced that it
would not consider a trial for publication unless the
clinical trial had been included in an approved registry.
ICMJE requirements stipulating trial registration as a
requisite for publication were announced in 2004 and
implemented through 2005, but due to retrospective
registration these registries also included a number of
clinical trials extending back as far as 2001.
Selection of clinical trials for review
We searched all identified registries for clinical trials re-
lated to uveitis, using the term “uveitis” within each reg-
istry’s electronic search capability, as a “free-text” search,
a “key-word” search, or both, depending on the available
options within the design of the registry. All registries
were included regardless of language. Screening of iden-
tified clinical trials were then undertaken to remove the
following types of studies, as shown in Fig. 1: duplicates;
studies in which uveitis patients were not the target
population; studies in which the primary outcome meas-
ure was not related to uveitis; studies of infectious uve-
itis; studies of anterior uveitis; and studies that were
non-interventional or retrospective in design.
Analysis of prospective interventional clinical trials
Studies that met inclusion criteria were analyzed according
to their primary outcome measure. Outcome measures
were transcribed verbatim from their register entry, then
classified according to type, dimension, and domain. The
type of outcome measure was described as being efficacy
only, safety only, or both; and as being a single measure, a
composite measure, or one of multiple, separate measures
used to determine clinical trial results. A composite out-
come measure was defined as one comprised of multiple
study variables, any one of which could signal achievement
of the outcome. For example, Suhler and associates de-
scribed a composite outcome measure labeled “clinical suc-
cess” comprised of the following study variables: visual
acuity; control of intraocular inflammation; ability to taper
concomitant medication therapy; and improvement in in-
flammatory signs on fluorescein angiography, ocular coher-
ence tomography, or both. Clinical success was achieved
when there was improvement in at least one study variable
and worsening of none [17]. In contrast, “multiple out-
comes” described those clinical trials in which more than
one separate study variable was listed as a primary outcome
measure, with apparent equal importance of each. and with
no pre-specification of their contribution to a single com-
posite score.
Dimension referred to whether the outcome measure
described (1) disease activity (e.g. presence or absence
of intraocular inflammatory signs and level of severity);
(2) tissue damage attributable to the disease or other
complications (e.g. cataract); (3) tested visual function
(e.g. visual acuity; or (4) patient-reported visual function
(e.g. NEI-VFQ-25 questionnaire). Domain described the
specific study variable that was being measured (e.g. anter-
ior chamber cell level or vitreous haze score for disease
activity).
The quality of each outcome measure was assessed on
the basis of definitions for each measure provided with
registration information. Specifically, we sought descrip-
tions about how study variables were to be categorized
or quantified. Outcome measures were deemed to be
poor quality, if, in the opinion of the reviewer, it would
not be possible to reproduce results independently on
the basis of the definitions provided.
Results
Identification of registries containing clinical trials
relevant to uveitis
At the time of database search (01 October 2013), 15
registries were identified that were endorsed by the
ICMJE. They included 11 national registries and four
international/multinational registries; the latter being the
International Standard Randomized Controlled Trial
Number Registry (ISRCTN), the European Union Clin-
ical Trials Register (EUCTR), the Pan African Clinical
Trial Registry (PACTR), and ClinicalTrials.gov. Of the
11 national registries, 10 are “stand-alone’ sites, whereas
the Japan Primary Registries Network represents a single
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portal to access three separate registries: the University
Hospital Medical Information Network (UHMIN); the
Japan Pharmaceutical Information Network (JAPIC);
and the Japan Medical Association Center for Clinical
Trials (JMACCT). Search of these databases identified
one or more clinical trials containing reference to “uve-
itis” in 10 of 15 registries (eight of 11 national registries
and three of four international registries, Table 1).
Identification of interventional trials related to uveitis
Screening of the ICMJE-approved registries identified
195 clinical trials related to uveitis. After removal of
duplicates, studies in which uveitis patients were not
the target population, studies in which the primary out-
come measure was not related to uveitis, studies of
infectious uveitis, and studies of anterior uveitis, 113
studies were identified that were potentially relevant to
this systematic review. In assessing eligibility by study
design, nine studies were found to be non-interventional
or retrospective, leaving 104 clinical trials for inclu-
sion. Of these 104 clinical trials, 101 (97 %) involved a
pharmacological agent, two (2 %) involved a surgical
intervention, and one (1 %) involved a cell-based
therapy.
Fig. 1 Flow chart depicting the process of identification, screening, and inclusion of uveitis clinical trials for this systematic review
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The Use of single, composite, and multiple primary
efficacy outcome measures in reviewed clinical trials
All 104 included clinical trials had pre-identified primary
outcome measures, which is a prerequisite for inclusion
on ICMJE-approved registries. Primary outcome mea-
sures involved efficacy in 91 (88 %) clinical trials; safety
in 10 (10 %) clinical trials; and both efficacy and safety
in three (3 %) clinical trials. For those 94 clinical trials in
which primary outcome measures involved efficacy, 36
(38 %) utilized a single efficacy variable (e.g. a two-step
change in the NEI vitreous haze score); 35 (37 %) uti-
lized a composite outcome (e.g. a score based on visual
acuity, control of inflammation, tapering of medication
therapy, and reduction of cystoid macular oedema [14]);
and 23 (24 %) utilized multiple separate outcome mea-
sures, either all related to efficacy (20 clinical trials) or a
mixture of efficacy and safety variables (3 clinical trials,
Table 2).
Of the 94 clinical trials in which primary outcome
measures involved efficacy, 75 included a broad range of
disorders (intermediate, posterior, and panuveitis),
whereas 19 were narrower in scope (18 involved only a
single disorder; one included two disorders). Of the 35
clinical trials that used a composite outcome measure,
28 included multiple categories of uveitis, whereas 7
were disorder-specific (5 involving Behcet disease; one
involving intermediate uveitis; and one involving multi-
focal choroiditis with panuveitis syndrome).
Analysis of Pre-identified primary efficacy outcome mea-
sures by dimension and domain
The 94 clinical trials that included one or more efficacy
outcome measures as the pre-specified primary outcome
measure were analysed further in terms of dimension
and domain. Overall 70 (74 %) of 94 clinical trials in-
cluded one or more measures of disease activity as a pri-
mary outcome measure; 49 (52 %) included one or more
measures of visual function (e.g. visual acuity) as a pri-
mary outcome measure; and 4 (4 %) included one or
more measures of tissue damage or other disease com-
plications as a primary outcome measure. No studies in-
cluded a measure of patient reported visual function as a
primary outcome measure. This prioritization of disease
activity, followed by visual function performance, and
then disease damage that we observed was not affected
by whether the registration pre-specified a primary out-
come measure involving a single efficacy variable; a
Table 1 Distribution of Trial Registrations. These figures include
studies registered across multiple registries
Registry Study Prefix Total
Australian New Zealand Clinical
Trial Registry
ACTRN 3
Brazilian Clinical Trials Registry ReBec 0
Chinese Clinical Trial Register ChiCTR 5
Clinical Trials Registry - India CTRI 8
Cuban Public Registry of Clinical Trials RPCEC 1
European Union Clinical Trials Register EudraCT 43
German Clinical Trials Register DRKS 0
International Standard Randomised
Controlled Trial Number Register
ISRCTN 9
Iranian Registry of Clinical Trials IRCT 4
Japan Primary Registries Network
comprising:
University Hospital Medical Information
Network
UMIN 5
Japan Pharmaceutical Information Center JAPIC 1
Japan Medical Association Center for
Clinical Trials
JMACCT 0
Korea National Institute of Health Clinical
Research Information Service
CRIS 0
Netherlands National Trial Register NTR 4
Pan African Clinical Trial Registry PACTR 0
Sri Lanka Clinical Trials Registry SLCTR 0
USA National Institute of Health Clinicaltrials.gov NCT 112
Total registrations 195
Table 2 Types of Primary Outcome selected for use in Registered Trials for Posterior Segment Involving Uveitis (PSIU)
Type of Primary Outcomes Design Number
(n/104)
Percentage
(%)
Efficacy Outcome(s) Alone Single efficacy outcome 36 35
Composite outcomes 35 34
Multiple efficacy outcomes 20 19
All 91 88
Safety Outcome Alone All 10 10
Mixed efficacy and Safety
Outcomes
Composite efficacy outcome
with safety outcome
0 0
Multiple efficacy outcome
with safety outcome
3 3
All 3 3
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composite outcome measure; or multiple outcome mea-
sures (Tables 3, 4 and 5).
Domain selection varied according to whether the
clinical trial pre-specified a primary outcome measure
that utilized a single efficacy variable, a composite out-
come measure, or multiple outcome measures. In stud-
ies that utilized a single efficacy variable, only three
activity domains were included: vitreous haze (eight of
18 clinical trials using an activity domain as a primary
outcome measure); macular oedema (8 clinical trials);
and treatment requirement (2 clinical trials). In clinical
trials with either a composite primary efficacy outcome
measure or multiple primary efficacy outcome measures,
six additional activity domains were utilized: anterior
chamber (AC) cells; AC flare; vitreous humour cells; vit-
reous “snow-balls”; chorioretinal inflammatory lesions;
and retinovascular inflammation. In nine clinical trials,
the outcome measure was listed as “activity”, but with-
out specification of the domain(s) measured to define
the measure. Vitreous haze was again the leading activity
domain utilized for clinical trials with a composite pri-
mary outcome measure (30 of 32 clinical trials using an
activity domain; p = 0.0002 vs. clinical trials with single
study variables as outcome measures; Fisher exact test),
but its use was significantly less common than in clinical
trials using multiple primary outcome measures (2 of 20
clinical trials using an activity domain; p = 0.0265 vs.
clinical trials with single study variables as outcome
measures; Fisher exact test). Use of macular oedema was
less common as an activity domain in clinical trials with
a composite outcome measure (four of 32 clinical trials
using an activity domain; p = 0.017 clinical trials with
single study variables as outcome measures; Fisher exact
test), but was used in a similar proportion of clinical tri-
als with multiple primary outcome measures (seven of
20 clinical trials with an activity domain; no significant
difference vs. clinical trials with single study variables as
outcome measures). Visual acuity was the domain used
to measure the dimension of visual function perform-
ance in all cases (Fig. 2).
The quality of pre-specified outcome measures was
considered to be poor in 12 (12 %) 0f 104 clinical trials;
for example, some used imprecise terms, such as “in-
flammation grade,” without specifying the variable to be
measured.
Discussion
There has been a lack of consensus with regard to the
outcome measures that should be collected in clinical
trials of efficacy for intermediate, posterior, and panuvei-
tis. In this systematic review, we analysed the outcome
measures used in all uveitis clinical trials included in all
ICMJE-approved clinical trial registries (from the reposi-
tory inception through to 01 October 2013). Consider-
able heterogeneity was noted, with at least 14 different
Table 3 Primary Outcomes classified by Dimension and
Domain: Single Efficacy Outcome Dataset
Dimension Domain Number
(n/36)
Percentage
(%)
Activity All 18 50
Vitreous haze 8 22
Macular
Oedema
8 22
Treatment
requirement
2 6
Damage/Other complications
of disease
All 4 11
Hypotony 2 6
Elevated IOP 1 3
Choroidal
neovascular
membrane
1 3
Visual function (performance) All 14 39
Visual acuity 14 39
Visual function (patient
reported)
All 0 0
Unspecified 0 0
Table 4 Primary Outcomes classified by Dimension and
Domain: Composite Efficacy Outcome Dataset
Dimension Domain Number
(n/35)
Percentage
(%)
Activity All 32 91
AC cells 21 60
Vitreous haze 30 86
Vitreous cells 2 6
Snowballs 1 3
Macular
Oedema
4 11
Chorioretinal
inflammatory
lesions
5 14
Retinovascular
inflammation
7 20
Treatment
requirement
10 29
Damage/Other
complications
of disease
All 0 0
Visual function
(performance)
All 22 63
Visual acuity 22 63
Visual function
(patient reported)
All 0 0
Unspecified 3 9
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domains being used as primary outcome measures.
Additionally, although pre-specified primary outcome
measures are required by these registries, the outcome
measures were poorly defined in a substantial number of
clinical trials, such that they provided inadequate infor-
mation for reproducibility. Furthermore, we noted that
23 (22 %) of 104 clinical trials had registered multiple
primary outcome measures, which is not recommended;
if fact, the CONSORT statement on reporting of clinical
trials specifically advises against doing so [18].
Before considering the challenging issue of outcome
measure heterogeneity further, it is worth noting the
specific outcome measures selected for the clinical tri-
als that have been registered. For the purposes of this
systematic review, we classified outcome measures into
distinct dimensions: disease activity (e.g. vitreous haze
score); disease-associated tissue damage or complica-
tions (e.g. cataract); visual function performance (e.g.
high-contrast distance visual acuity); and patient-
reported visual function (e.g. NEI-VFQ-25). Of the in-
cluded studies that addressed efficacy, 74 % included
one or more variables related to disease activity as pri-
mary outcome measures; 52 % included visual acuity as
a primary outcome measure and 4 % included one or
more variables of disease-associated tissue damage or
complications as primary outcome measures. No stud-
ies included a measure of patient reported visual func-
tion as a primary outcome measure.
It may be argued that these dimensions reflect a dis-
ease pathway viewed from opposite ends by the clinician
(who makes treatment decisions based primarily on dis-
ease activity) and the patient (whose primary concern is
the impact of the disease on function and quality of life).
All four dimensions are inter-related, but the relation-
ship between them is complex. For example, increasing
central macular thickness (CMT) due to macular edema is
associated with worsening visual acuity, and worsening
visual acuity is associated with worsening patient-reported
visual function, but the relationship is not necessarily direct,
and the correlation between them is not perfect [19–22].
The most common measures of disease activity used
as primary outcome measures were vitreous haze and
macular oedema. It is interesting to contrast these do-
mains. Vitreous haze, as assessed using the NEI vitreous
haze score, is a subjective measure, with a substantial in-
terobserver variability (agreement, k = 0.53 for exact
grade; k = 0.75 for within 1 grade), and as discussed earl-
ier, is additionally limited by the narrow range seen in
association with most forms of uveitis (scores of 0, 0.5+,
1+; less commonly 2+) [14, 15]. In contrast, macular
oedema, as assessed by optical coherence tomography
can provide objective measures of high reproducibility
(e.g. automated measurement of CMT) which are highly
sensitive to detecting change [22, 23]. It is important to
recognize that these domains are measuring different
aspects of the disease, and that many patients with
vitreous inflammatory reactions will not have macular
oedema and vice versa. The impact of OCT in the meas-
urement of macular oedema does, however, highlight the
value that objective quantification by imaging modalities
(including, but not limited to OCT) might in the future
bring to the assessment of vitreous inflammatory reac-
tions, chorioretinitis, retinal vasculitis, and other mani-
festations of disease activity in intermediate, posterior,
and panuveitis [8, 24].
It is noteworthy that all clinical trials that included
measures of visual function performance, used high-
contrast distance visual acuity. Although distance visual
acuity is a standard assessment in almost all ophthalmic
studies, it is increasingly recognized to be an imperfect
indicator of day-to-day visual function [8]. Other com-
ponents of visual function that might be considered
Table 5 Primary Outcomes classified by Dimension and
Domain: Multiple Efficacy Outcome Dataset
Dimension Domain Number
(n/23)
Percentage
(%)
Activity All 20 87
AC cells 4 17
AC flare 2 9
Vitreous haze 2 9
Vitreous cells 1 4
Snowballs 1 4
Macular Oedema 7 30
Chorioretinal
inflammatory
lesions
2 9
Retinovascular
inflammation
3 13
Treatment
requirement
4 17
Unspecified
‘activity’
9 39
Damage/Other
complications
of disease
All 4 17
Elevated IOP 3 13
Cells on IOL 1 4
Posterior
capsular
opacification
1 4
Visual function
(performance)
All 13 57
Visual acuity 13 57
Visual function
(patient reported)
All 0 0
Unspecified 0 0
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include contrast sensitivity, reading acuity, reading
speed, visual field sensitivity, and central retinal sensi-
tivity [21, 25, 26]. The utility of determining these vari-
ables to assess the impact of uveitis on quality of life is
not yet established, but their inclusion as secondary
outcome measures in therapeutic clinical trials may
provide valuable information in this regard.
The impact of altered visual function on quality of life
may be objectified through patient reported outcome
measures (PROM), such as the NEI-VFQ25 [27, 28]. The
NEI-VFQ25 has been validated for patients with cata-
ract, age-related macular degeneration, diabetic eye dis-
ease and glaucoma [28], but its validation among those
with uveitis has been more limited [29]. Although the
preferred PROM for most clinical trials related to uveitis
has been the NEI VFQ-25, it is likely that not all of its
questions are equally relevant to this population [29–31].
The HURON study reported that, although results for all
Fig. 2 Column graphs depicting domains and selected dimensions used in pre-specified primary outcome measures of efficacy in uveitis clinical
trials. a, b Dimensions according to whether primary outcome measure was single, multiple, or composite. c Activity domains, according to
whether primary outcome measure was single, multiple, or composite
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questions differed significantly from the normal-vision
population [32], only near-vision, distance vision, periph-
eral vision and social functioning questions showed
significant change with treatment [33]. It is of interest that
we found no uveitis clinical trials that included patient-
reported variables as a primary outcome measures, even
when multiple or composite outcome measures were
used. It is important that those involved in the design of
uveitis clinical trials recognize the value of such outcome
measures in providing the patient perspective and captur-
ing a more holistic response to a given treatment (and its
side-effects) than is provided by more familiar outcome
measures such as visual acuity. Although not the primary
focus of this systematic review, we did note that patient-
reported outcome measures (such as the NEI-VFQ25) are
being used with increasing frequency as secondary out-
come measures. The use of these secondary outcome
measures is likely to provide additional, valuable informa-
tion that will help inform patients, clinicians, and other
stake-holders, as to the broader benefit of a therapeutic
agent under consideration.
The field of uveitis is not alone in facing the problem
of heterogeneous outcome measures in drug develop-
ment. In a survey of 2000 trials dealing with schizophre-
nia, Thornley and Adams found that 640 different
instruments had been used, of which 369 had been used
only once [34]. In choosing outcome measures, CON-
SORT strongly encourages the use of “previously devel-
oped and validated scales or consensus guidelines …
both to enhance quality of measurement and to assist in
comparison with similar studies” [18]. Doing so matters
because heterogeneity of outcome renders comparison
of clinical trials and meta-analyses difficult or even im-
possible. In rare diseases, where the number of trials will
always be more limited, it is even more important that
there is consensus regarding the selection of outcome
measures so that such evidence can be gathered to
inform patients, clinicians, regulators and healthcare
funders.
While our systematic review does not attempt to pro-
vide the solution to outcome heterogeneity in the study
of uveitis, it does provide an estimate of the scale of the
problem and provides data to inform this important de-
bate. The variation in outcome measures chosen by the
investigators of these 104 clinical trials is, in itself, an in-
dicator that there is likely to be no easy answer to the
problem. Approaches to finding a solution may need to
face the “lumping vs. splitting” dichotomy among uveitis
specialists. For example, Behcet disease, pars planitis
syndrome, birdshot chorioretinopathy, and Vogt-
Koyanagi-Harada disease are distinct forms of uveitis,
with unique signs of inflammation, yet all have, in the
past, ended-up in common clinical trials that use the
same outcome measures. The risk is that one may fail to
detect therapeutic benefit due to the high level of “noise”
introduced by the amalgamation of too-wide a range of
clinical entities for two reasons. First, this grouping is
based on a taxonomy which reflects anatomy rather than
aetiology, and so it cannot be assumed that a particular
therapy will be equally efficacious across all uveitis syn-
dromes within the same group. Second even if a drug
were to be effective across multiple syndromes (due to
overlapping pathogenetic pathways), there may be no
single outcome measure that can adequately detect a
positive response in all these different syndromes, each
of which has a unique phenotype. The option of
syndrome-specific clinical trials has not been possible,
despite making “biological sense”, because of logistic
challenges, particularly around recruitment. There is also
a pragmatic issue with disease-specific clinical trials: the
narrower in scope the population within a clinical trial,
the narrower any subsequent regulatory approval will be.
Others have tackled the issue of heterogeneous out-
come measures in clinical trials by establishing “core
outcome sets” (COS). This approach provides a stan-
dardized set of outcome measures that are reported in
all clinical trials of a condition under consideration,
while still allowing the investigator discretion to choose
his or her own primary or secondary outcome measures
[35]. The use of COS may enhance evidence synthesis
by reducing heterogeneity (shared outcome measures),
reducing outcome-reporting bias (as the whole COS is
reported) and improving the statistical power of any
meta-analysis (more studies can be included). COS de-
velopment is supported by a number of initiatives, such
as COMET (Core Outcome Measures in Effectiveness
Trials) and has been endorsed by the Cochrane Library,
the GRADE (Grading of Recommendations Assessment,
Development and Evaluation) working group, and the
WHO [35, 36].
Another strategy relevant to this debate is the use of a
composite outcome measure. While it may be argued
that such outcome measures provide a more “holistic”
assessment of a patient’s state (they frequently include
visual acuity), it is likely that the frequent use of com-
posite measures in the clinical trials that we reviewed
(35 of 94 clinical trials with an efficacy measure) is
driven by the lack of a single outcome measure suitable
for all patients. This is supported by the observation that
of these 94 clinical trials, 75 included a broad range of
disorders (intermediate, posterior, and panuveitis), with
only 18 being limited to a single disorder (and one study
including two disorders). It should be noted that the de-
sign, use, and interpretation of composite endpoints is a
challenging area, and has led to the FDA to put strict
guidance in place as to their usage [37].
It is also important to consider how study variables
are measured [35]. Although it was not the primary
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focus of this review, we noted considerable heterogen-
eity with regard to how a number of domains were
measured. For example, visual acuity varied between
clinical trials with regard to (1) measurement instru-
ment (i.e. Snellen or the ETDRS chart); and (2) quanti-
fication (e.g. “improvement in 2 or more lines of
Snellen visual acuity” or “improvement in LogMAR” by
a specified number of letters). Similarly, the use of the
NEI vitreous haze score varied with regard to quantifi-
cation (number of steps required to be significant), and
in some trials an additional scoring point (1.5+) was
added.
We chose to limit our review to clinical studies in
ICMJE-approved registries, for a number of reasons. It
identifies all studies in which the investigators have pre-
specified primary outcome measures and trial design; it
reduces publication bias; and it provides a more current
perspective on trial design than provided by published
articles, most of which do not describe the full protocol,
as it existed prior to commencement of the clinical trial.
We conducted the analysis on an ‘intention-to-trial’
basis; all registered clinical trials were included, regard-
less of whether or not they were later withdrawn, failed
to recruit participants, or completed recruitment, but
were never published. We felt that doing so was import-
ant, as there is substantial publication bias around clin-
ical trials that fail to demonstrate a desired therapeutic
benefit. This approach also ensured that we identified
what the trialists perceived to be the most appropriate
primary outcome measures at the time of trial design,
rather than at the time of publication, thereby avoiding
the publication bias that may have arisen from investiga-
tors selecting those outcome measures that provided a
significant result instead of those that were pre-
specified.
We recognise that our systematic review omitted a
number of older studies of uveitis that predated the
ICMJE requirements for registration. In its September
2004 editorial, the ICMJE announced that it would not
consider a trial for publication unless the clinical trial
had been included in an approved registry. Registration
had to be undertaken prospectively (i.e. prior to patient
enrolment) for any clinical trial starting enrolment after
July 1, 2005. For clinical trials that began enrolment prior
to that date, registration had to occur by September 13,
2005. Our review should therefore have a complete record
of relevant clinical trials from the past 8 years, and due to
retrospective registration in 2005, a number of additional
clinical trials extending back as far as 2001.
In summary our systematic review formally surveys
the heterogeneity present around outcome measures in
recent and current clinical trials related to intermediate,
posterior, and panuveitis. It does not address the issue of
outcome measures for anterior uveitis, an important
form of disease, but one that has not been the subject of
many therapeutic clinical trials to date. We have
reported that current clinical trial designs in uveitis
prioritize clinician-observed measures of disease activity
and objective measurements of visual function, and that
patient-reported outcome measures did not feature as
primary outcome measures in any registered clinical trial
to date. We argue that the challenging issue of outcome
measure selection for clinical trials of efficacy related to
uveitis needs to be addressed, and that the uveitis com-
munity needs to work towards a new consensus regard-
ing an approach to the use of outcome measures in
therapeutic clinical trials involving patients with uveitis.
Competing interests
Dr. Denniston and Dr Kidess have no conflicts of interest to declare.
Dr. Holland has served on Advisory Boards for the following companies:
Genentech, Incorporated; Novartis International AG; Santen, Incorporated;
and Xoma (US) LLC.
Dr. Okada has received lecture fees from the following companies: Novartis
Pharma K.K. (Japan); Bayer Yakuhin, Ltd. (Japan); Mitsubishi Tanabe Pharma
Corporation; Pfizer Japan, Inc.; and Santen Pharmaceutical Co., Ltd. She has
also served on Advisory Boards or provided consultation for the following
companies: Novartis AG; Novartis Pharma K.K. (Japan); Bayer Healthcare AG;
and Xoma Corporation.
Dr Rosenbaum has received clinical trial support from Genentech, Lux,
Abbvie, Celgene, Xoma, Eyegate and Bristol-Myers Squibb. He has also served
as a consultant for Genentech, Allergan, Santen, Xoma, Regeneron, Sanofi,
Teva, EMD Serono, Novartis, UCB and Abbvie. He also receives financial
support from the NIH and the Spondylitis Association of America. Prof. Dick
has served on Advisory Boards for the following companies: Novartis, Abbvie
and Qchips.
Authors’ contributions
AKD conceived the study, participated in the design of the study, and
performed the analysis. AK carried out the database searches. All authors
(AKD, AK, GNH, RBN, AAO, JTR, ADD) helped to draft the manuscript and
provided guidance on the analyses undertaken. All authors read and
approved the final manuscript.
Author details
1Institute of Translational Medicine, Birmingham Health Partners, University of
Birmingham, Birmingham, UK. 2Department of Ophthalmology, Queen
Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS
Foundation Trust, Birmingham, UK. 3UCLA Stein Eye Institute and the
Department of Ophthalmology, Ocular Inflammatory Disease Center, David
Geffen School of Medicine at UCLA, 100 Stein Plaza, UCLA, Los Angeles, CA
90095-7000, USA. 4National Eye Institute, National Institutes of Health,
Bethesda, Maryland, USA. 5Department of Ophthalmology, Kyorin University
School of Medicine, Tokyo, Japan. 6Department of Ophthalmology, Casey Eye
Institute, Oregon Health & Science University, USA Legacy Devers Eye
Institute, Portland, Oregon, USA. 7Bristol Eye Hospital, University Hospitals
Bristol NHS Foundation Trust, Bristol, UK. 8Academic Unit of Ophthalmology,
University of Bristol, Bristol, UK. 9NIHR Biomedical Research Centre for
Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL
Institute of Ophthalmology, London, UK.
Received: 18 March 2015 Accepted: 6 August 2015
References
1. Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease.
Ophthalmologica. 2004;218(4):223–36.
2. Williams GJ, Brannan S, Forrester JV, Gavin MP, Paterson-Brown SP,
Purdie AT, et al. The prevalence of sight-threatening uveitis in Scotland. Br J
Ophthalmol. 2007;91(1):33–6.
Denniston et al. Orphanet Journal of Rare Diseases  (2015) 10:97 Page 10 of 11
3. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and
frequency of blindness in patients with intraocular inflammatory disease. Br
J Ophthalmol. 1996;80(4):332–6.
4. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern
California;the Northern California Epidemiology of Uveitis Study.
Ophthalmology. 2004;111(3):491–500.
5. Vadot E, Barth E, Billet P. Epdemiology of uveitis- preliminary results of a
prospective study in Savoy. In: Saari K, editor. Uveitis update. Amsterdam:
Elsevier; 1984. p. 13–6.
6. Jones NP. The Manchester Uveitis Clinic: The First 3000 Patients-Epidemiology
and Casemix. Ocul Immunol Inflamm. 2013 Dec 2. [Epub ahead of print]
PubMed PMID: 24295124.
7. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis
nomenclature for reporting clinical data. Results of the First International
Workshop. Am J Ophthalmol. 2005;140(3):509–16.
8. Denniston AK, Dick AD. Systemic therapies for inflammatory eye disease: past,
present and future. BMC Ophthalmol. 2013;13:18. doi:10.1186/1471-2415-13-18.
9. Sreekantam S, Denniston AK, Murray PI. Survey of expert practice and
perceptions of the supporting clinical evidence for the management of
uveitis-related cataract and cystoid macular oedema. Ocul Immunol
Inflamm. 2011;19(5):353–7. doi:10.3109/09273948.2011.592260.
10. Lowder C, Belfort Jr R, Lightman S, Foster CS, Robinson MR, Schiffman RM,
et al. Ozurdex HURON Study Group. Dexamethasone intravitrealimplant for
noninfectious intermediate or posterior uveitis. Arch Ophthalmol.
2011;129(5):545–53. doi:10.1001/archophthalmol.2010.339.
11. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen
JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, et al. Randomized
comparison of systemic anti-inflammatory therapy versus fluocinolone
acetonide implant for intermediate, posterior, and panuveitis: the
multicenter uveitis steroid treatment trial. Ophthalmology.
2011;118(10):1916–26. doi:10.1016/j.ophtha.2011.07.027.
12. Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, et al.
Risk of elevated intraocular pressure and glaucoma in patients with uveitis:
results of the multicenter uveitis steroid treatment trial. Ophthalmology.
2013;120(8):1571–9. doi:10.1016/j.ophtha.2013.01.025.
13. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal
inflammatory activity in intermediate and posterior uveitis. Ophthalmology.
1985;92(4):467–71.
14. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement
in grading activity and site of inflammation in eyes of patients with uveitis.
Am J Ophthalmol. 2008;146(6):813–8. doi:10.1016/j.ajo.2008.06.004. Epub
2008 Aug 8. PubMed.
15. Hornbeak DM, Payal A, Pistilli M, Biswas J, Ganesh SK, Gupta V, et al.
Interobserver Agreement in Clinical Grading of Vitreous Haze Using Alternative
Grading Scales. Ophthalmology. 2014. doi:10.1016/j.ophtha.2014.02.018.
16. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al.
Increasing value and reducing waste: addressing inaccessible research.
Lancet. 2014;383(9913):257–66. doi:10.1016/S0140-6736(13)62296-5. Epub
2014 Jan 8. PubMed PMID: 24411650.
17. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. A
prospective trial of infliximab therapy for refractory uveitis: preliminary safety
and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–12. PubMed.
18. Schulz KF, Altman DG, Moher D, for the CONSORT Group.CONSORT
Checklist. Available at http://www.consort-statement.org/checklists/view/32-
consort/80-outcomes. [Last accessed 16 March 2015]
19. Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, et al.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.
Identifying a clinically meaningful threshold for change in uveitic macular
edema evaluated by optical coherence tomography. Am J Ophthalmol.
2011;152(6):1044–52. doi:10.1016/j.ajo.2011.05.028. e5.
20. Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical
coherence tomography may be used to predict visual acuity in patients
with macular edema. Invest Ophthalmol Vis Sci. 2011;52(5):2741–8.
doi:10.1167/iovs.09-4493.
21. Taylor SR, Lightman SL, Sugar EA, Jaffe GJ, Freeman WR, Altaweel MM, et al.
The impact of macular edema on visual function in intermediate, posterior,
and panuveitis. Ocul Immunol Inflamm. 2012;20(3):171–81. doi:10.3109/
09273948.2012.658467.
22. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, et al.
Quantitative assessment of macular edema with optical coherence
tomography. Arch Ophthalmol. 1995;113(8):1019–29.
23. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M,
Rothenbuehler SP, et al. Macular thickness measurements in healthy eyes
using six different optical coherence tomography instruments. Invest
Ophthalmol Vis Sci. 2009;50(7):3432–7.
24. Keane PA, Karampelas M, Sim DA, FRCOphth, Sadda S, Tufail A, Sen HN,
Nussenblatt RB, Dick AD, Lee RW, Murray PI, Pavesio CE, Denniston AK.
Objective Measurement of Vitreous Inflammation using Optical Coherence
Tomography Ophthalmology 2014 May 15. doi: 10.1016/j.ophtha.2014.03.006
25. Kiss CG, Barisani-Asenbauer T, Maca S, Richter-Mueksch S, Radner W.
Reading performance of patients with uveitis-associated cystoid macular
edema. Am J Ophthalmol. 2006;142(4):620–4.
26. Munk M, Kiss C, Huf W, Sulzbacher F, Bolz M, Sayegh R, et al. Therapeutic
interventions for macular diseases show characteristic effects on near and
distance visual function. Retina. 2013;33(9):1915–22.
27. Denniston AK, Kyte D, Calvert M, Burr JM. An introduction to patient-
reported outcome measures in ophthalmic research. Eye (Lond).
2014;28(6):637-45.
28. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD.
Development of the 25-list-item National Eye Institute Visual Function
Questionnaire. Arch Ophthalmol. 2001;119(7):1050–8.
29. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general
health status in patients with uveitis. Arch Ophthalmol. 2001;119(6):841–9.
30. Murphy CC, Greiner K, Plskova J, Frost NA, Forrester JV, Dick AD. Validity of
using vision-related quality of life as a treatment end point in intermediate
and posterior uveitis. Br J Ophthalmol. 2007;91(2):154–6.
31. Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, et al.
Multicenter Uveitis Steroid Treatment-MUST Trial Research Group.
Associations among visual acuity and vision- and health-related quality of
life among patients in the multicenter uveitis steroid treatment trial. Invest
Ophthalmol Vis Sci. 2012;53(3):1169–76.
32. Naik RK, Rentz AM, Foster CS, Lightman S, Belfort Jr R, Lowder C, et al.
Normative comparison of patient-reported outcomes in patients with
noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219–25.
33. Lightman S, Belfort Jr R, Naik RK, Lowder C, Foster CS, Rentz AM, et al.
Vision-related functioning outcomes of dexamethasone intravitreal implant
in noninfectious intermediate or posterioruveitis. Invest Ophthalmol Vis Sci.
2013;54(7):4864–70.
34. Thornley B, Adams C. Content and quality of 2000 controlled trials in
schizophrenia over 50 years. BMJ. 1998;317:1181–4.
35. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al.
Developing core outcome sets for clinical trials: issues to consider. Trials.
2012;13:132. doi:10.1186/1745-6215-13-132.
36. Core Outcome Measure in Effectiveness Trials Initiative. Available at
http://www.comet-initiative.org[Last accessed 16 March 2015].
37. U.S. Department of Health and Human Services Food and Drug
Administration. Guidance for Industry Patient-Reported Outcome Measures:
Use in Medical Product Development to Support Labeling Claims. Available
at http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf [Last
accessed 16 March 2015].
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Denniston et al. Orphanet Journal of Rare Diseases  (2015) 10:97 Page 11 of 11
